Related Experiment Video

Updated: Jul 16, 2026

Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds
08:23

Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds

Published on: February 16, 2022

Relevance of nitric oxide for myocardial remodeling

Paul B Massion1, Jean-Luc Balligand

  • 1Unit of Pharmacology and Therapeutics (FATH 5349), Department of Medicine, Université Catholique de Louvain, 53 Avenue Mounier, 1200 Brussels, Belgium.

Current Heart Failure Reports
|March 28, 2007
PubMed

Insights

Endogenous nitric oxide (NO) impacts heart remodeling. Endothelial NOS (eNOS) offers protection against heart failure by acting as an "endogenous beta-blocker," promoting repair and potentially serving as a therapeutic target.

Area of Science:

  • Cardiovascular Physiology
  • Molecular Cardiology
  • Biomedical Research

Background:

  • Endogenous nitric oxide (NO) plays a critical role in modulating myocardial remodeling.
  • The role of NO synthase (NOS) isoforms in heart failure is complex and context-dependent.
  • Oxidative stress and NOS enzyme status significantly influence NO's effects on the heart.

Purpose of the Study:

  • To elucidate the specific roles of different NOS isoforms in myocardial remodeling.
  • To investigate the cardioprotective mechanisms of endothelial NOS (eNOS) in cardiac disease.
  • To explore therapeutic strategies targeting eNOS for heart failure treatment.

Main Methods:

  • Utilized rodent models of pressure overload and myocardial infarction.
  • Analyzed the function of neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial NOS (eNOS) isoforms.
  • Assessed the impact of NO production, NOS localization, and oxidant balance on cardiac remodeling.

Main Results:

  • Endothelial NOS (eNOS), when coupled, demonstrates significant cardioprotective effects against various cardiac insults.
  • eNOS functions as an endogenous beta-blocker, improving sympathovagal balance and promoting tissue repair.
  • The beneficial effects of common heart failure drugs are mediated by eNOS.

Conclusions:

  • eNOS is a key mediator of cardioprotection in myocardial remodeling and heart failure.
  • Strategies enhancing eNOS expression and activity represent promising therapeutic avenues for heart failure.
  • Maintaining eNOS coupling is crucial for its protective functions in the myocardium.

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...